Summary
Edwards Lifesciences Corporation's (EW) 2013 10-K filing highlights robust growth, particularly in its Transcatheter Heart Valve (THV) segment, which saw sales increase by 28.2% year-over-year, driven by strong performance in both the US and international markets. This growth in THV, coupled with modest increases in Surgical Heart Valve Therapy, helped offset a slight decline in Critical Care sales. The company's overall net sales increased by 7.7% to $2.05 billion. Financially, EW demonstrated improved profitability, with diluted EPS growing by 38.7% to $3.44. This was bolstered by a favorable product mix, increased sales volume, and a significant one-time gain of $52.3 million (net of tax) from a litigation award against Medtronic. The company continues to invest heavily in research and development, with R&D expenses rising to 15.8% of net sales, underscoring its commitment to innovation in structural heart disease and critical care monitoring. Looking ahead, EW faces increasing competition in the transcatheter valve market but is well-positioned due to its established leadership and ongoing development of next-generation products like the SAPIEN 3 valve. The company's financial position remains strong, supported by healthy operating cash flow and a significant share repurchase program.
Financial Highlights
53 data points| Revenue | $2.05B |
| Cost of Revenue | $516.60M |
| Gross Profit | $1.53B |
| R&D Expenses | $323.00M |
| SG&A Expenses | $733.40M |
| Interest Expense | $9.80M |
| Net Income | $389.10M |
| EPS (Basic) | $0.58 |
| EPS (Diluted) | $0.57 |
| Shares Outstanding (Basic) | 670.20M |
| Shares Outstanding (Diluted) | 682.80M |
Key Highlights
- 1Net sales grew 7.7% to $2.05 billion in 2013, driven by strong performance in Transcatheter Heart Valves (+28.2%).
- 2Transcatheter Heart Valves now represent 35% of total net sales, up from 20% in 2011, indicating a significant shift in product mix.
- 3Diluted EPS increased by 38.7% to $3.44, reflecting improved operational performance and a significant litigation award.
- 4Research and Development (R&D) spending increased by 10.9% to $323.0 million, representing 15.8% of net sales, highlighting a focus on innovation.
- 5The company received FDA approval for the SAPIEN 3 valve in Europe in January 2014 and initiated US studies, signaling continued investment in next-generation transcatheter technologies.
- 6A significant litigation award of $83.6 million from Medtronic was received in February 2013, positively impacting net income.
- 7The company repurchased $495.1 million of its common stock in 2013, demonstrating a commitment to returning capital to shareholders.